Questions regarding use of infliximab and risk of certain viral infections.
El-Matary
Wael
W
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D006562:Herpes Zoster / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008991:Monitoring, Physiologic; D018570:Risk Assessment; D014777:Virus Diseases / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology
D000911:Antibodies, Monoclonal; D000069285:Infliximab